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ABSTRACT 
Ubiquicidin is an antimicrobial peptide (AMP) with great potential for nuclear imaging of 
infectious diseases as its cationic-rich fragment TGRAKRRMQYNRR (UBI) has been 
functionalized with 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) to allow complexation to 
Gallium-68 (68Ga-NOTA-UBI). We herein assess the cytotoxicity, radiation dosimetry for 68Ga-
NOTA-UBI and a first-in-human evaluation to diagnose infectious processes. Methods: 
Cytotoxicity was evaluated in green monkey kidney epithelial (Vero) cells and MT-4 leucocytes. 
Tracer susceptibility was studied in vitro using different bacterial and fungal strains. Positron 
Emission Tomography-Computed Tomography (PET-CT)-based biodistribution, 
pharmacokinetics and radiation dosimetry were carried out in non-human primates (NHP). Two 
healthy volunteers and three patients with suspected infection underwent 68Ga-NOTA-UBI-PET-
CT imaging. Results: Negligible cytotoxicity was determined for NOTA-UBI. 68Ga-NOTA-UBI 
showed moderate blood clearance (29 min half-life) and predominant renal clearance in NHP. 
Human radiation dose estimates indicated the bladder wall as the dose-critical tissue (185 
µSv/MBq) followed by kidneys (23 µSv/MBq). The total absorbed body dose was low (<7 
µSv/MBq); the effective dose was estimated at 17 µSv/MBq. 68Ga-NOTA-UBI was capable to 
diagnose bone- and soft-tissue infection in 3/3 patients. Conclusion: 68Ga-NOTA-UBI is 
considered a non-toxic, safe-to-administer radiopharmaceutical unlikely to cause adverse 
effects in humans. The favorable tracer biodistribution and the first-in-human results will make 
68Ga-NOTA-UBI-PET-CT an encouraging future diagnostic technique with auxiliary clinical 
relevance. 
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INTRODUCTION 
Conventionally, bacterial infections are diagnosed by clinical examination, characteristic 
symptoms and culturing of microorganisms from blood, urine or sputum samples. Radiological 
techniques, such as ultrasound or CT may be helpful but are not always able to differentiate 
septic from aseptic processes and only identify anatomical changes related to late stage 
infections while Magnetic Resonance Imaging (MRI) cannot be applied in patients suffering from 
claustrophobia or bearing implanted medical devices. 
Scintigraphy and PET can track radiolabeled leukocyte infiltration into the infection site using a 
whole-body imaging approach and allow for early detection of infectious areas well before 
anatomical changes occur (1). Approved radiopharmaceuticals to assess infectious diseases 
include in vitro or in vivo radiolabeled leukocytes, 18F-fluorodeoxyglucose (18F-FDG), 67Ga-
citrate, and radiolabeled antibodies targeting leukocyte antigens (2). However, these tracers 
show considerable variation in accuracy to diagnose infections (3). Therefore the development 
of bacteria-specific imaging probes is a promising alternative to more reliably detect infections 
(4,5). Radiolabeled antibiotics, vitamins, other biomimetics, AMP and bacteriophages have been 
highlighted as potential infection imaging agents (6-10).  
AMP such as ubiquicidin are used as targeting vectors for molecular imaging because of their 
selectivity for bacterial cell membranes in the innate immune system response (11). Studies of 
cation-rich ubiquicidin fragments, including TGRAKRRMQYNRR (UBI) (12) have shown them to 
be useful as infection nuclear imaging agents. This peptide, directly labeled with technetium-
99m (99mTc), shows preferential binding to bacterial rather than mammalian cells in vitro and 
allows identification of infected sites and better discrimination from the surrounding sterile or 
inflamed tissue in animals and human subjects (13-15). While Single-Photon Emission 
Computed Tomography is a widely available technique, PET may be superior in terms of its 
image resolution, sensitivity and quantification. Therefore a 68Ga-radiolabeled PET derivative of 
UBI was developed, meeting the physiological half-life of peptides (16) and using a biological 
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targeting vector (i.e. peptide bioconjugates). Chelation with bi-functional chelator molecule 
NOTA (17-19) was used to conjugate UBI allowing for 68Ga-radiolabeling (20). Upon 
radiosynthesis, a successful preclinical evaluation as a bacteria-selective imaging was approved 
in three different rabbit models (21). Before clinical applications, the safety of 
radiopharmaceuticals, to a certain extent, needs to be determined towards tolerability and 
possible side effects of the radiotracer (22). We therefore aimed to demonstrate that 68Ga-
NOTA-UBI can be used as a safe radiopharmaceutical for human applications by achieving 
results regarding its in vitro cytotoxicity, biodistribution and estimated human radiation dosimetry 
in NHP. In addition, we report the results of a first-in-human study on the imaging performance 
of 68Ga-NOTA-UBI-PET-CT in patients with suspected infection. 
 
 
MATERIALS AND METHODS 
A supplement data file provides details for material and some methods 
(http://jnm.smnjournals.org). 
 
nat/68Ga-labeling of NOTA-UBI: NOTA-functionalized UBI was labeled “cold” with 
gallium(III)chloride (natGaCl3) (for in vitro assays) or radiolabeled in a sterile, pyrogen-free 
fashion with 68Ge/68Ga generator-derived (iThemba LABS, Somerset West, South Africa) 
68Ga[Cl4]- (all in vivo applications) as described previously (20).  
 
Cytotoxicity: Vero cells were utilized studying any noxious potential of NOTA, NOTA-UBI and 
natGa-NOTA-UBI according to a previously described method (23). Additionally, cytotoxicity to 
MT-4 leucocytes was determined by compound dose escalation or calculating the half-maximal 
inhibitory concentration (IC50) (24). 
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Antibacterial and antifungal susceptibility: Bacterial susceptibility was determined using the 
broth micro-dilution method (25) on freshly cultured bacterial strains using a final working 
suspension of 106 cells/mL. The fungal susceptibility was evaluated in yeast strains by a method 
described elsewhere (26) using a working suspension of 5×103 cells/mL. 
 
68Ga-NOTA-UBI pharmacokinetics and tracer biodistribution in NHP: The study enrolled 
three NHP according to the South African code of practice for the care and use of animals. 
Ethical approval was given by the Pretoria University (Reference: H001-09). Adult vervet 
monkeys (Chlorocebus aethiops) were obtained from the Biomedical Research Centre 
(Onderstepoort, Pretoria University). Animals were handled as previously described (27). Image 
acquisition started 30, 60 and 120 min after intravenous administration of 68Ga-NOTA-UBI using 
a PET-CT scanner (Biograph True Point 40-slice CT; Siemens/CTI, Knoxville, TN, USA). 
Arterial blood samples and urine were collected. Tissue and organ uptake were calculated as 
percentage of injected dose (%ID); tracer activity concentration was represented by 
standardized uptake value (SUV). 
 
Dosimetric analyses in NHP: Radiation absorbed doses were calculated according to the 
Medical Internal Radiation Dose method (OLINDA/EXM 1.0) for internal dose assessment (28).  
 
PET-CT imaging in humans: Two healthy volunteers and three patients with known/suspected 
infection were approved for this first-in-human study by the institutional Ethics Committee. 
Nuclear imaging was carried out using a previously published procedure (27).  
 
Statistical Analyses: Results were expressed as mean and standard deviation (±SD) or 
standard error of mean (±SEM). 
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RESULTS 
Cytotoxicity: Cytotoxicity was tested by escalating compound concentrations in Vero cells 
(Supplement Fig. 1) and by standard IC50 calculations in MT-4 leukocytes. Vero cells sustained 
cellular viability upon the maximum treatment concentration of 200 μM (P>0.05). The 
percentage of viable cells was calculated as 97.7 ± 4.1, 98.1 ± 2.1, 95.8 ± 3.7, 90.8 ± 8.3, and 
96.6 ± 3.7 for UBI, NOTA-UBI, natGa-NOTA-UBI, natGa-NOTA, and the control, respectively. A 
significant cytotoxic response was found with 0.1-4 ppm CdCl2 (positive control); the percentage 
of viable cells seemingly decreased with increasing CdCl2 amounts (r2=0.85). Thus, CdCl2 
caused significant differences in comparison to all tested compounds (P<0.01). Leukocytes 
exhibited no cytotoxicity; the normalized IC50 values (mM) were calculated as 340, 270, and 260 
for UBI, NOTA-UBI, and natGa-NOTA-UBI respectively. No substantial leukocyte toxicity 
occurred upon treatment with the control (Indinavir, IC50=301 nM).  
 
Antimicrobial and antifungal susceptibility: None of the UBI derivatives tested appeared to 
exhibit substantial antibacterial or antifungal activity and cased insignificant inhibition of bacterial 
/ fungal growth up to a maximum concentration (0.2 mg/mL), being 10000-fold higher than the 
tracer concentration considered in human blood following intravenous administration. In the 
same assay the minimal inhibitory concentrations (µg/mL) of neomycin were 0.32, 0.87, 2.0, and 
32.6 for S. aureus, B. subtilis, E. coli, and P. aeruginosa respectively. The minimal inhibitory 
concentrations (µg/mL) determined for clotrimazole were 0.04, 0.03 and 1.0 for C. albicans 
24433, C. albicans 90028, and C. parasilopsis respectively. 
 
68Ga-NOTA-UBI imaging, pharmacokinetics and biodistribution in NHP: NHP were injected 
with 33-45 MBq/kg 68Ga-NOTA-UBI (244 ± 50 MBq - decay-corrected, specific activity 13.8 ± 1.9 
GBq/µmol). A 3.5-6.5 mL saline bolus contained 29.7 ± 2.1 nmol NOTA-UBI (distributed as 72 ± 
19 pmol/mL blood) (Supplement Table 1). Maximum image projection (MIP) PET-CT showed 
by KU Leuven University Library on February 1, 2018. For personal use only. jnm.snmjournals.org Downloaded from 
early-onset tracer biodistribution with the highest tracer concentrations in the bladder, kidneys, 
liver and heart (Fig. 1). Significant tracer washout over 120 min was determined for blood, 
heart, spleen, lung, stomach, thyroid, bone, genitals and muscle. The SUV of all other organs 
were similar or lower than seen for the musculoskeletal tissue (Supplement Table 2). The time-
activity curves resulting from blood and urine sampling are illustrating relatively rapid tracer 
blood clearance (2.64 %ID/h) (Supplement Fig. 2) and the distribution fitted an exponential 
function (29 min half-life, r2=0.77; N=19; Cmax=0.49 ± 0.19 %ID/g). The radioactivity was 
recovered predominately via the renal excretion route as follows: 15.4 %ID/h excretion rate, 74 
± 4 %ID cumulative percentage recovery voiding over 120 min, Cmax = 39 ± 8 %ID (r2=0.90; 
N=17). 
 
Estimation of human absorbed doses by extrapolating data from 68Ga-NOTA-UBI 
biodistribution in NHP: Human radiation doses represent the organ related burden to a normal 
sized adult. The extrapolated tracer biodistribution in humans based on 68Ga-NOTA-UBI 
injection into NHP is summarized in Supplement Table 3. Absorbed doses (Table 1) were 
calculated from integrated organ residence times (Supplement Table 4). The effective dose 
was 17 ± 6 µSv/MBq, estimating a total human dose range between 3.1 and 4.3 mSv/tracer 
administration. Due to the dominant renal excretion route, the radioactive burden was the 
highest in the bladder wall and kidneys. Secondary critical organ was liver and lung. All other 
values were ≤10 µSv/MBq. A low total body dose of <7 µSv/MBq was absorbed. 
 
PET-CT imaging in humans: Two 18 year-old healthy volunteers (m/f) and three patients 
(m/f/f; age range 34‐69 years) with known/suspected bone- and/or soft-tissue infections 
received 174 ± 42 MBq (range: 129-240 MBq) 68Ga-NOTA-UBI corresponding to 22.5 ± 3.8 
nmol (range: 21.3-25.5 nmol) of NOTA-UBI (Supplement Table 1). Patients did not suffer from 
any acute adverse reaction such as altered blood pressure, rashes, itching, flushing, nausea, 
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coughing, muscle cramps or dizziness upon tracer injection (no long-term adverse effects were 
reported either). PET images showed tracer accumulation in kidneys and bladder, representing 
renal excretion (Fig. 2). Minimal radioactivity was noted in liver and myocardium (including 
vasculature system). The tracer concentration (N=5; SUVmean ± SD) for heart, lung, liver, spleen, 
kidneys, urinary bladder and muscle tissue were respectively 2.3 ± 0.4, 0.57 ± 0.09, 1.8 ± 0.8, 
1.4 ± 0.5, 11 ± 8, 21 ± 6, and 0.32 ± 0.05. In 3/3 patients (100%), 68Ga-NOTA-UBI-PET-CT 
accurately identified the infectious area that have also been confirmed by other techniques. All 
68Ga-NOTA-UBI-PET images showed a significantly higher SUV at the infection site than the 
respective reference tissues (P< 0.05) resulting in high target-to-background ratios and good 
delineation of the infectious regions. A representative image of two patients with acute / chronic 
osteomyelitis in the ankle joint and an extending soft tissue infection into the legs, confirmed by 
radiography and bone scintigraphy is shown (Fig. 3). Figure 4 shows a spinal infection in a 69-
year-old patient which was confirmed by MRI and further clinical testing. The SUVmax in the 
infection sites was 3.3 ± 0.3 and the SUVmean of infected tissue was 3.1-3.6-fold higher 
compared to the contralateral, uninfected tissue (P< 0.001). 
 
DISCUSSION 
Novel approaches have been proposed and made to conquer challenges in imaging infectious 
diseases, including discriminating infection from sterile inflammation, spread of infection and 
therapy monitoring (5,29). It is known that even slight modifications of a molecule may 
significantly alter its biological properties, hence necessitating evaluation of any tracer derivative 
to determine its efficacy and safety prior to human administration (30,31). 
 
Toxicity: Our in vitro testing showed minimal cellular toxicity to cultured Vero cells suggesting 
negligible toxicity to patients. Moreover, the antimicrobial activity against selected bacterial and 
fungal strains showed minimal toxicity which is expected since it would be counter-productive 
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for AMP. They are naturally found in human bodies and other mammals, and never exhibit 
significant toxicity towards the organism’s host cells (7,32,33). The lack of antimicrobial activity 
is advantageous for this diagnostic agent because killing of the targeted bacteria could result in 
trafficking of dead pathogens and the attached tracer to remote sites, thereby distorting the 
image and interpretation as to the extent of the infectious focus (32,34). The observed lack of 
antimicrobial activity was in contradiction with the results of Brouwer et al. (22). UBI has been 
reported to exhibit noteworthy toxicity against methicillin-resistant Staphylococcus aureus; 
however, a non-methicillin-resistant, laboratory staphylococcal strain and different methods 
were used in this study. AMP susceptibility to methicillin-resistant Staphylococcus aureus was 
also proven for other peptides (35). Despite the lacking susceptibility, an uncompromised 
bacterial binding affinity was reported for 68Ga-NOTA-UBI (6,20,36). Lupetti et al. (37) studied 
the antifungal activity of UBI against Aspergillus fumigates hyphae and reported an IC50 
concentration of 0.15 ± 0.03 mg/mL. Although the fungi species was different, antifungal activity 
against Aspergillus fumigates and Candida spp. was minimal. As with antibacterial activity, 
antifungal activity is not required but unabridged binding affinity is desired for radiodiagnostic 
agents facilitating infection imaging.  
 
68Ga-NOTA-UBI imaging and dosimetry: As an AMP, UBI was expected to be non-
immunogenic and considered non-toxic, which initially fast tracked its evaluation for 
scintigraphic imaging (38). 99mTc-UBI29-41 was administered to humans to study 
pharmacokinetics following tracer injection in vivo (39). Thereafter, the first-in-human study 
enrolled patients with infection of the bone, soft-tissue, or prostheses. No adverse effects 
occurred following 99mTc-UBI29-41 imaging of the infectious scenarios (14). Recently, we have 
shown that NOTA conjugation of UBI29-41 did not compromise the targeting ability of this AMP 
fragment to selectively bind to the bacterial cell envelope (20). At present, no published study 
focused on the safe administration of 68Ga-NOTA-UBI and its translation into clinical 
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applications. We were able to generate initial findings during a proof-of principle investigation 
where 68Ga-NOTA-UBI was safely administered to rabbits bearing muscular infection paired 
with a contralateral sterile inflammation site (21). Similar results from another research group 
support our findings using infected mice. The tracer was found stable in PBS and blood samples 
(36,40). All animals seem to have tolerated the tracer injections well; it seems safe to conclude 
that there is a negligible risk concerning the administration of 68Ga-NOTA-UBI.  
Herein, we demonstrated radiation dosimetry estimates in NHP translatable to human 
applications of 68Ga-NOTA-UBI. These should be considered preliminary results based on a 
setup with three male vervet monkeys undergoing 68Ga-NOTA-UBI-PET-CT to study blood 
clearance, tissue biodistribution, tracer excretion and estimation of radiation doses. The vervet 
monkey biomedical model is reported to suit several investigations such as behaviourism, 
metabolism and immunity (41). The similar blood distribution volume to humans (60-70 mL/kg) 
make NHP models ideal to translate advanced radiopharmaceuticals into humans as they can 
provide significant information regarding tracer biodistribution or dosimetry. The bolus injection, 
activity concentration, specific activity and total peptide mass injected in NHP mimicked those 
considered for human application, yet the lower body weight of the monkeys increased the 
administered dose by 15-fold as compared to human doses. The study design included simple 
access to blood and urine samples which allowed meeting statistical compliance in a small 
number of animals compared to rodents. The pharmacokinetics showed the desired radioactivity 
blood clearance over 60 min p.i. (P<0.001). Based on this result, the first-in-human 
investigations, presented herein, were set for static imaging at 60 min after tracer injection. As 
an advantage, the lacking hepatobiliar tracer excretion may suggest 68Ga-NOTA-UBI-PET for 
diagnostic of abdominal infection. The overall radiation dose and the dose to regenerative 
tissues such as red marrow, osteogenic cells, ovaries and gonads were favourably low (<10 
µSv/MBq). Since the scope of the study allowed only for male monkeys, radiation dose 
estimates for ovaries, uterus and breasts relied on the assumption that the tracer biodistribution 
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is similar for women and men. The bladder was voided in order to create urine samples and to 
mimic the clinical setup where the patients void the bladder ahead of imaging. The human dose 
range was calculated as 3.1-4.3 mSv per 68Ga-NOTA-UBI administration which adheres well to 
the guidelines regarding the maximum exposure for a single radioactive injection in Europe (10 
mSv) (42). No comparative dosimetry of other 68Ga-labeled infection imaging agents is currently 
available. The radiation dose for one 68Ga-NOTA-UBI dose is significantly lower than 
considered for 18F-FDG (P<0.05) and 3.5-times less than the radiation dose of 68Ga-DOTA-
TATE, another diagnostic 68Ga-tracer used in humans (43,44). 
 
PET-CT imaging in humans: This first-in-human study evaluating the diagnostic performance 
of 68Ga-NOTA-UBI-PET-CT was performed in three patients with known/ suspected bone-or soft 
tissue infection. Except for the renal clearance and excretion, biodistribution in humans was 
similar to NHP and no significant differences were observed between healthy volunteers and 
patients with the exception of tracer accumulation in the infectious area. The accumulation of 
68Ga-NOTA-UBI over 60 min was sufficient to delineate the infectious tissues, as shown by a 
target-to-nontarget ratio of 3.4 ± 0.2 which is significantly higher (P<0.05) than reported values 
for 99mTc-UBI29-41 (2.3 ± 1.3; N=18) or 99mTc-HYNIC-UBI29-41 (1.9 ± 0.3; N=5) (14,45). Our 
pilot study demonstrates the capability of this imaging technique to detect infected tissues as 
confirmed by other techniques. Based on this targeting approach, tracer uptake is reflected by 
the bacterial burden rather than inflammatory cell influx as observed with PET imaging using 
18F-FDG or radiolabeled leucocytes. We described previously that the NOTA-UBI uptake follows 
an exponential dependence (R2 >0.66) with rising amounts of bacteria (gram+/-) residing in the 
infection site (46). Similar to NOTA-UBI, the novel bacteria-specific PET-probe 2-fluoro-18F-
desoxysorbitol was developed in mice, tested recently in healthy volunteers, and is expected to 
diagnose enterobacteriaceae-specific infection in humans (47,48). The host-independent 
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targeting mechanism of UBI could qualify 68Ga-NOTA-UBI-PET-CT as imaging modality to 
facilitate future differential diagnostics of infectious diseases. 
 
Study scope and limitations: Some limitations of this study included that tracer 
pharmacokinetics, biodistribution, and dosimetry data were obtained from anaesthetized NHP 
which could affect the hemodynamics of various organs and may affect tracer uptake. Although 
the blood flow to the liver is altered less by isoflurane than by other anaesthesia methods, renal 
blood flow and urine production are decreased by isoflurane in mice (49). General anaesthesia 
could also affect the metabolism of 68Ga-NOTA-UBI, similar to a significant reduction in brain 
glucose metabolism observed with 18F-FDG (50). This study only allowed for three male NHP, 
which has limited statistical power and assumptive information on radiation burden in females. 
Due to the avid urinary tracer excretion, inferior imaging of urinary tract infections or infections in 
the pelvis (surrounding the bladder) may occur. However; favorable renal excretion was seen in 
human subjects than in NHP. Also, administering diuretics, bladder voiding or catheterization 
can significantly lower the dose to the bladder wall. Even though there is a major advantage of 
using radiolabeled AMP (they retain at the site of infection by internalization and subsequent 
amplification) imaging of phagocytosed microorganism may be limited (13) which can result in 
an underestimation of the actual bacterial burden. 
 
CONCLUSION 
This study demonstrates that 68Ga-NOTA-UBI is a non-toxic, safe-to-administer 
radiopharmaceutical unlikely to cause adverse effects in humans. Biodistribution corresponds to 
major peptide-metabolizing organs and predominantly urinary excretion. 68Ga-NOTA-UBI-PET-
CT was able to accurately identify all infectious foci in the three patients with suspected 
infection. Even though the first-in-human results are encouraging, further clinical studies are 
required to assess the diagnostic accuracy of 68Ga-NOTA-UBI for imaging infectious diseases.  
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FIGURE LEGENDS (+ figures in reduced resolution) 
 
FIGURE 1. 
Representative 68Ga-NOTA-UBI-PET-CT biodistribution in a NHP 60 min after tracer 
administration (189 MBq)  
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FIGURE 2. 68Ga-NOTA-UBI-PET MIP image (skull to mid-thigh) demonstrating physiological 
tracer biodistribution in a healthy (A) male and (B) female volunteer. Images were acquired 60 
min after intravenous injection of 132 MBq (♀) and 129 MBq (♂) tracer. 
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FIGURE 3. Representative 68Ga-NOTA-UBI-PET-CT image in a patient with peripheral bone- 
and soft-tissue infection. (A) Whole-body MIP-PET image shows a diffusely increased tracer 
uptake in the right lower leg. (B) Detailed PET-CT images demonstrate focal increased tracer 
uptake in the ankle-joint extending in the adjacent bone (black and white arrows) as well as 
diffuse tracer uptake in the calf muscles (red arrow) whereas there is no significant uptake in the 
contralateral leg. Images are obtained 60 min after tracer administration (240 MBq)  
 
 
 
by KU Leuven University Library on February 1, 2018. For personal use only. jnm.snmjournals.org Downloaded from 
 
FIGURE 4. Representative MRI and 68Ga-NOTA-UBI-PET-CT imaging in a patient with 
suspected spinal infection (spondylodiscitis). (A) Coronal T1 weighted MRI image (fat 
suppression), (B) whole-body MIP-PET image, and (C) sequential transaxial fused PET-CT 
(top), PET (middle) and CT (bottom) images showing focal increased uptake in the 
intervertebral region of L3-L4 corresponding to the abnormal findings on MRI. K=kidney.
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TABLES 
 
TABLE 1 
Extrapolated Human Radiation Dose Estimates for 68Ga-NOTA-UBI 
Organ Dose (µSv/MBq) %CV 
Adrenals  6.21  5.0 
Brain  1.16 9.5 
Breast 4.95 7.4 
Gallbladder wall 6.84 5.5 
Lower left intestine 8,50 15.5 
Small intestine 7.58 7.0 
Stomach wall 6.56 2.4 
Upper left intestine 7.28 6.9 
Heart wall 10.0 6.8 
Kidneys 23.1 19.0 
Liver 17.7 27.9 
Lung 11.7 13.3 
Muscle 3.70 9.7 
Ovaries 7.60 10.0 
Pancreas 6.15 21.0 
Red marrow 6.67 5.6 
Osteogenic cells 9.64 5.8 
Skin 4.59 5.2 
Spleen 7.67 15.5 
Testes 5.01 25.6 
Thymus 5.35 6.7 
Thyroid 3.55 4.5 
Urinary bladder wall 185 58.6 
Uterus 10.3 22.2 
Total Body 6.84 0.6 
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MATERIAL 
Media, chemicals and equipment: Solvents, reagents, drugs and culture media were 
purchased from commercial sources in highest purity and used as recommended. NOTA-UBI 
was purchased from GL Biochem Ltd. (Shanghai, China). To determine mammalian cell toxicity, 
an automated PowerWave XS2 microplate reader (Biotek Instruments, Winooski, VT, USA) 
measuring optical density (OD), was utilized.  
Bacteria, fungi and laboratory animals: Vero cells and MT-4 human leukocytes from LGC 
Standards (Johannesburg, South Africa) were used to assess in vitro cytotoxicity. Bacterial cells 
(Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 25923), Pseudomonas 
aeruginosa (ATCC 27853), Bacillus subtilis (ATCC 6051)) and fungi (Candida albicans (ATCC 
24433), Candida albicans (ATCC 90028) and Candida parasilopsis (ATCC 22019)) were 
obtained from the National Health Laboratory Services (Inkosi Albert Luthuli Hospital, Durban, 
South Africa) to test for compound susceptibility.  
METHODS  
Antibacterial and antifungal susceptibility: Freshly-cultured bacterial strains were suspended 
to 106 cells/mL; the yeast working suspension was adjusted to 1-5×103 cells/mL using a mixture 
containing RPMI (with L-glutamine, without bicarbonate) (Cambrex Bio Science, Verviers, 
Belgium) and 0.165 M morpholine propane sulfonic acid (MOPS) (Sigma-Aldrich, Germany) 
buffered to pH 7.0. NOTA, NOTA-UBI, natGa-NOTA and natGa-NOTA-UBI were dissolved in 10 
% acetonitrile. Clotrimazole (0.0012 - 80 μg/mL) and Neomycin (both, Sigma, Germany) (0.0015 
- 100 μg/mL) were used as reference drugs.  
Dosimetric analyses: The following organs (heart, liver, spleen, lung, brain, thyroid, stomach, 
bone (femur), testes, muscle, pancreas, small and large intestines, kidneys and urinary bladder) 
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were identified as source organs and delineated. From these delineations, %ID per volume was 
determined and converted to %ID for humans using the following conversion formula:  
 
Organ weights and whole-body weight of the male human phantom were used as representative 
values and converted to volume values using density values of 1.04, 1.40 and 0.296 g/cm3 for 
soft tissue, bone and lungs respectively. Blood activity was assumed to be the same as for red 
marrow. Heart wall and heart content were included in the organ volume. Volumes of the 
intestinal tract and the urinary bladder contents were included but not the organ walls. For the 
different sub-organs, the activity was weighted based on the relative volumes. Finally, the %ID 
of the remainder was determined such that the total %ID adds up to 100%. 
PET-CT imaging in humans: A brief description of the patient characteristics:1) A 37-year-
old male patient presented with a suspicion of unilateral (right) ankle joint infection and 
osteomyelitis (OM), which was suggested on a prior bone scintigraphy. He presented 
with recurring leg pain suspicious for infectious spread into the surrounding soft tissue 
and calf muscle. Biochemical inflammatory parameters were significantly increased.  
2) A 34-year-old female patient was diagnosed with septic OM in the right ankle based 
99mTc-WBC scintigraphy. She presented with recurring pain and swelling in the ankle joint 
and drainage of serosanguinous fluid.  
3) A 69-year-old female patient with a history of discitis presented with worsening pain and 
increased inflammatory parameters (ESR=16 mm/hr, CRP=105, white cell count= 6.45 x 
109/L). CT-scan showed end-plate sclerosis from L2-L4 with wedge shaped volume loss 
of L3/L4. A prior MRI confirmed a L2/3 to L3/4 spondylodiscitis with significant erosion 
and collapse of the vertebral bodies with features suggestive of pyogenic 
spondylodiscitis/spondylitis.  
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Whenever possible, blood cultures and bacteriology were carried out to confirm the presence of 
infection. The results of clinical tests, radiography and bone scintigraphy were used in cases in 
which culturing of tissue samples could not be performed.  
Statistical Analyses: Experiments were performed in triplicate unless otherwise stated. Where 
indicated, representative data from individual experiments are shown. Statistical significance 
was determined using the Student-t test (paired and unpaired). A value of (*) P<0.05, (**) 
P<0.01 and (***) P<0.001 were considered statistically significant. 
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RESULTS 
 
SUPPLEMENT FIGURE 1.    
Cellular toxicity of ubiquicidin peptide derivatives in Vero cells. Average values across five 
replicates are presented. Standard error of mean display was omitted due to clarity (0.4-3.7% at 
5 µM, 1.0-4.5% at 40 µM, 0.9-8.3% at 200 µM). UBI: ubiquicidin fragment 29-41; NOTA-UBI: 
NOTA-functionalized ubiquicidin fragment 29-41; Ga-NOTA-UBI: NOTA-functionalized 
ubiquicidin fragment 29-41 complexed with natGa; Ga+NOTA: NOTA complexed with natGa; 
Control: peptide coded GDEAEEMQYNEE (i.e. a negatively charged UBI fragment - any 
arginine (cationic charge) are replaced by aspartic acid (anionic charge)).
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SUPPLEMENT FIGURE 2.    
Time-dependent activity concentration of 68Ga-NOTA-UBI showing blood clearance (A) and 
urine recovery (B) calculated from samples yielded from three vervet monkeys. Animals were 
injected intravenously with 38.9 ± 6.2 MBq/kg bodyweight. Data from available blood follows an 
exponential decline (y=0.424e-0.017x; r2= 0.877, N=19). Data from urinary activity recovery shows 
a linear incline (y=0.252x; r2=0.904, N=17). 
 
 
 
 
 
SUPPLEMENT TABLE 1. 
Comparison of 68Ga-NOTA-UBI Application in NHP and Humans 
Characteristic Vervet 
Monkeys* 
Human† 
Age (y); Sex (m/f) > 8; m 35 ± 19; m/f 
Body weight (kg) 6.8 ± 1.6 68 ± 22 
Administered activity (MBq) 227 ± 27 174 ± 42 
Administered dose (MBq/kg) 39 ± 6 2.7 ± 0.8 
 
*) Results are expressed as mean values (± sem) for N= 3. 
†) Results are expressed as mean values (± sem) for N= 5. 
f=female; m=male 
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 SUPPLEMENT TABLE 2. 
Image-guided Organ Activity Concentration of 68Ga-NOTA-UBI in NHP 
Organ /Tissue 
Concentration (SUV)† 
30 min 60 min 120 min 
Blood (arcus aortae)  1.11 ± 0.15 0.81 ± 0.09* 0.49 ± 0.05* 
Heart  1.22 ± 0.07 0.78 ± 0.11 0.43 ± 0.04** 
Liver  3.12 ± 0.73 2.72 ± 0.87 2.42 ± 0.87 
Spleen  1.26 ± 0.21 0.95 ± 0.25 0.79 ± 0.29* 
Lung  0.66 ± 0.09 0.43 ± 0.05* 0.25 ± 0.03* 
Brain  0.09 ± 0.02 0.05 ± 0.01 0.04 ± 0.01 
Thyroid  0.45 ± 0.03 0.29 ± 0.05 0.20 ± 0.07* 
Stomach  0.42 ± 0.08 0.33 ± 0.11 0.21 ± 0.08* 
Bone (femur)  0.36 ± 0.09 0.26 ± 0.02 0.17 ± 0.03* 
Genitals (testes)  0.51 ± 0.13 0.40 ± 0.10* 0.29 ± 0.11** 
Muscle (reference tissue)  0.31 ± 0.02 0.18 ± 0.02* 0.12 ± 0.02* 
Pancreas  0.80 ± 0.27 0.47 ± 0.09 0.30 ± 0.02 
Intestines (small & large)  0.40 ± 0.19 0.28 ± 0.04 0.16 ± 0.02 
Kidneys  4.67 ± 0.88 3.56 ± 0.68 2.79 ± 0.12 
Bladder, urinary tract  26.4 ± 16.3 49.0 ± 16.5 35.6 ± 20.9 
 
†) Average standard uptake value (SUVmean) quantification from PET-CT imaging; results 
are expressed as average SUV (± SEM) for N=3. Two-way paired Student-t tests were 
performed comparing values of 60/120 min to values of 30 min: (*) P ≤0.05 and (**) P 
≤0.01.  
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 SUPPLEMENT TABLE 3. 
Extrapolated Tracer Biodistribution in Humans based on 68Ga-NOTA-UBI Injection into NHP 
Organ / Tissue 
Biodistribution (% ID/Gram)† 
30 min 60 min 120 min 
Red marrow 1.22 ± 0.17 0.64 ± 0.07* 0.21 ± 0.03* 
Heart wall 0.37 ± 0,02 0.17 ± 0.03* 0.05 ± 0.01** 
Heart 0.55 ± 0,02 0.26 ± 0.04* 0.08 ± 0.01** 
Stomach 0.11 ± 0.02 0.06 ± 0.02* 0.02 ± 0.01* 
Liver 5.80 ± 1.34 3.68 ± 1.23* 1.79 ± 0.66* 
Spleen 0.23 ± 0.04 0.12 ± 0.03* 0.06 ± 0.02** 
Lung 2.25 ± 0.31 1.06 ± 0.14* 0.35 ± 0.05* 
Brain 0.13 ± 0.03 0.05 ± 0.01 0.02 ± 0.001* 
Pancreas 0.07 ± 0.03 0.03 ± 0.01 0.01 ± 0.001 
Thyroid 0.01 ± 0.001 0.004 ± 0.001* 0.002 ± 0.001** 
Bone (Femur) 1.05 ± 0.26 0.56 ± 0.06 0.20 ± 0.04* 
Genitals (Testes) 0.02 ± 0.01 0.01 ± 0.003* 0.04 ± 0.002* 
Intestines 0.31 ± 0.14 0.16 ± 0.02 0.05 ± 0.01 
Small intestine 0.16 ± 0.07 0.08 ± 0.01 0.03 ± 0.004 
Upper left intestine 0.09 ± 0.04 0.05 ± 0.001 0.02 ± 0.003 
Lower left intestine 0.06 ± 0.03 0.03 ± 0.004 0.01 ± 0.002 
Kidneys 1.36 ± 0.25 0.76 ± 0.15 0.32 ± 0.02* 
Bladder & urinary tract 5.4 ± 3.3 7.3 ± 2.3 2.9 ± 1.6 
Remainder of body 47 ± 5 36 ± 2* 22 ± 2** 
 
†)  decay-corrected organ activity uptake in percentage of the total injected 
dose (ID) per gram; results are expressed as %ID/gram (±SEM) for N=3 
animals. Two-way paired Student-t tests were performed comparing values of 
60/120 min to values of 30 min: (*) P ≤0.05 and (**) P ≤0.01.  
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 SUPPLEMENT TABLE 4. 
Organ Residence Times for 68Ga-NOTA-UBI Estimated from Biodistribution Data in NHP 
Organ/ Tissue* 
Residence Time (h) 
Mean SD 
Heart wall 3.55×10-3 3.12×10-4 
Brain 1.22×10-3 3.57×10-4 
Upper left intestine 9.50×10-4 5.03×10-4 
Lower left intestine 6.30×10-4 3.32×10-4 
Small intestine 1.58×10-3 8.34×10-4 
Stomach 1.05×10-3 2.98×10-4 
Kidneys 1.36×10-2 2.91×10-3 
Liver 5.97×10-2 1.86×10-2 
Lung 2.17×10-2 3.58×10-3 
Muscle 8.27×10-2 8.94×10-3 
Pancreas 5.73×10-4 1.96×10-4 
Red marrow 1.18×10-2 1.90×10-3 
Cortical bone 1.01×10-2 2.62×10-3 
Spleen 2.23×10-3 4.92×10-4 
Testes 1.87×10-4 6.66×10-5 
Thyroid 8.80×10-5 5.00×10-6 
Blood 5.32×10-3 4.73×10-4 
Urine 1.57×10-1 9.54×10-2 
Remainder 5.35×10-1 4.70×10-2 
 
*) No residence times could be calculated for 
adrenals, breast, gallbladder, ovaries, thymus, uterus 
and trabecular bone. 
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